Bio-Rad Laboratories, Inc. (BIO): Price and Financial Metrics
Bio-Rad Laboratories, Inc. (BIO)
Today's Latest Price: $589.19 USD
Updated Jan 21 4:00pm
Add BIO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
BIO Stock Summary
- BIO's went public 35.08 years ago, making it older than 92.82% of listed US stocks we're tracking.
- BIO's current price/earnings ratio is 5.09, which is higher than just 3.91% of US stocks with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, Bio-Rad Laboratories Inc is reporting a growth rate of 736.88%; that's higher than 98.11% of US stocks.
- Stocks that are quantitatively similar to BIO, based on their financial statements, market capitalization, and price volatility, are PKI, CERN, GNRC, ATHM, and SNN.
- Visit BIO's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-rad.com.
BIO Stock Price Chart Interactive Chart >
BIO Price/Volume Stats
| Current price | $589.19 | 52-week high | $648.39 |
| Prev. close | $600.81 | 52-week low | $309.38 |
| Day low | $586.17 | Volume | 258,499 |
| Day high | $601.41 | Avg. volume | 255,687 |
| 50-day MA | $578.38 | Dividend yield | N/A |
| 200-day MA | $515.34 | Market Cap | 17.58B |
Bio-Rad Laboratories, Inc. (BIO) Company Bio
Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.
BIO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $589.19 | $258.37 | -57% |
Below please find a table outlining a discounted cash flow forecast for BIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 33th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Bio-Rad Laboratories Inc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 196.01 -- which is good for besting 97.7% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 14% of the free cash flow producing stocks we're observing.
- BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 45.83% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -58% |
| 1% | -57% |
| 2% | -57% |
| 3% | -57% |
| 4% | -56% |
| 5% | -56% |
Want more companies with a valuation profile/forecast similar to that of Bio-Rad Laboratories Inc? See MD, BAX, GILD, HAPP, and JNJ.
Loading social stream, please wait...